Arcus Biosciences Inc expected to post a loss of 95 cents a share - Earnings Preview

Arcus Biosciences

07/05/2024 03:25

* Arcus Biosciences Inc  RCUS.N   RCUS.K  is expected
to show a
rise in quarterly revenue when it reports  results on May 8 for
the period ending March 31 2024
    * The Hayward California-based  company is expected to
report a
35.4% increase in revenue to $33.863 million from $25 million a
year ago, according to the mean estimate from 8 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Arcus Biosciences Inc is
for a
loss of 95 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Arcus
Biosciences
Inc is $36.00​, above​ its last closing price of $15.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.00       -1.02      -1.08     Missed  -5.5
 Sep. 30 2023  -1.12       -1.13      -0.94     Beat    16.7
 Jun. 30 2023  -1.09       -1.10      -1.04     Beat    5.3​
 Mar. 31 2023  -1.17       -1.16      -1.09     Beat    6.3
 ​​Dec.        -1.02       -1.07      -0.93     Beat    12.8
 31 2022                                                
 Sep. 30 2022  -1.03       -1.04      -0.90     Beat    13.3​
 Jan. 1 0001   -0.94       -0.94      -0.93     Beat    1.2
 Mar. 31 2022  -0.83       -0.86      -0.96     Missed  -11.5
 This summary was machine generated May 7 at 02:25 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)